Cooperative Agreement 90AX0028

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Washington University in the amount of $737,815 supports the development and validation of an automated Electronic Health Record (EHR)-embedded system to rapidly classify molecular phenotypes of acute respiratory distress syndrome (ARDS) and sepsis. The goal is to enable future precision medicine trials for these critical illnesses, which lack effective...

This Project Grant award of $718,958, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), is for developing and rigorously testing a digital shared decision-making tool to improve patient-centered outcomes in implantable cardioverter-defibrillator (ICD) decisions among older patients. The award recipient, The Leland Stanford Junior University, will refine the user experience of the digital tool, develop visual data displays,...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,604 to Case Western Reserve University to develop and validate a novel transfer volume regression model. This model aims to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The project will leverage commonly used, low-cost screening programs to...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $707,410 to Duke University, with a sub-award to Emory University, to develop solutions for overcoming inequities in pulse oximetry through clinical informatics. The key objectives are to: 1) Use electronic health record data to develop machine learning models to predict patients at high risk for hidden hypoxemia due to pulse oximetry inaccuracies, and identify...

The National Institutes of Health's Office of the Director awarded a $8,661,331 project grant under the Lung Diseases Research program (CFDA 93.838) to the Massachusetts General Hospital on June 10, 2021 for the development of interactive data portals and analytic tools to support Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) cohorts. Key products and services delivered through Massachusetts General Hospital and several sub-awardees include an interactive data portal called the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports the development and pilot testing of the Promoting Palliative Care for People with Heart Failure (P3HF) clinical decision support (CDS) tool. The primary goal is to design the P3HF CDS, which incorporates a 1-year mortality risk model, and develop an implementation package to facilitate clinician referrals to specialist...

This Cooperative Agreement award for $650,398 from the National Center on Birth Defects and Developmental Disabilities, under the Disabilities Prevention program (CFDA 93.184), supports efforts to advance the surveillance of congenital heart defects (CHD) in Indiana. The key products and services being delivered include: Conducting population-based surveillance of infants, adolescents, and adults with CHD to identify predictors and outcomes, including for adults with CHD (ACHD). Developing and...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $321,363 to Nucleusrx, Inc. to develop and test a virtual care platform and remote intervention tool targeting post-acute care heart failure (HF) patients. The goal is to create a solution that enables healthcare providers to implement a safe discharge transition plan from hospital to home, while allowing rapid optimization of...